Zacks Investment Research on MSN
AstraZeneca gets FDA nod for new hypertension drug Baxfendy
AstraZeneca AZN announced that the FDA has approved baxdrostat for treating adult patients with uncontrolled or ...
Adding the novel medication baxdrostat to standard care may help manage high blood pressure and delay the progression of kidney disease in people with chronic kidney disease and uncontrolled high ...
Aldosterone synthase inhibition targets upstream aldosterone production, differentiating baxdrostat from mineralocorticoid ...
Anyone who recalls the 1971 Loving Care commercial exclaiming, 'You're not getting older. You're getting better!' is getting older. America is graying -- in 2019, people older than 65 years accounted ...
The FDA has approved baxdrostat (Baxfendy), the first oral aldosterone synthase inhibitor, for adults with uncontrolled ...
Among older adults with frailty, evidence on the benefits and risks of discontinuing antihypertensive drugs is limited. In a multicenter, randomized, controlled trial conducted in France, we assigned, ...
Patients on antihypertensive medications who still struggle with high blood pressure now have a new treatment option, following the U.S. FDA’s approval of Astrazeneca plc’s baxdrostat. Branded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results